Marshall Wace, LLP Beyond Spring Inc. Transaction History

Marshall Wace, LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$9.37 - $12.12 $603,802 - $781,012	-64,440 Reduced 33.47%	128,116 $1.34 Million
Q1 2021 May 17, 2021	BUY	$10.61 - $15.77 $320,803 - $476,821	30,236 Added 18.63%	192,556 $2.13 Million
Q4 2020 Feb 16, 2021	BUY	$10.21 - $17.31 $984,111 - $1.67 Million	96,387 Added 146.19%	162,320 $1.98 Million
Q3 2020 Nov 16, 2020	SELL	$9.99 - $16.13 $237,841 - $384,023	-23,808 Reduced 26.53%	65,933 $877,000
Q2 2020 Aug 13, 2020	BUY	$11.21 - $18.15 $1.01 Million - $1.63 Million	89,741 New	89,741 $1.35 Million

5.26M

12.1K

Ticker BYSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,928,900
Market Cap $68.9M
Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.